Penile cancer survival statistics

Survival

Survive penile cancer for 10 or more years, 2009-2013, England

 

Age

Age that penile cancer survival is highest, 2009-2013, England

 

89% of men survive penile cancer for at least one year, and this is predicted to fall to 74% surviving for five years or more, as shown by age-standardised Open a glossary item net survival for patients diagnosed with penile cancer during 2009-2013 in England.[1]

Penile Cancer (C60), Age-Standardised One-, Five- and Ten-Year Net Survival, Men (Aged 15-90), England, 2009-2013

1-Year Survival (%) 5-Year Survival (%) 10-Year Survival (%)
Men Net Survival 88.7 73.9 68.4
95% LCL 87.0 71.1 63.7
95% UCL 90.1 76.4 72.7

95% LCL and 95% UCL are the 95% lower and upper confidence limits Open a glossary item
 
Five- and ten-year survival is predicted using an excess hazard statistical model
 

Penile cancer survival is similar at five and ten years after diagnosis.68% of men are predicted to survive their disease for ten years or more, as shown by age-standardised net survival for patients diagnosed with penile cancer during 2009-2013 in England.[1

References

  1. Muller P, Belot A, Morris M, Rachet B, Cancer Research UK Cancer Survival Group, London School of Hygiene and Tropical Medicine. Net survival and the probability of cancer death from rare cancers. Available from http://csg.lshtm.ac.uk/rare-cancers/. Accessed July 2016.

About this data

Data is for: England, 2009-2013, ICD-10 C60

Last reviewed:

Five-year survival for penile cancer is highest in the youngest men and decreases with increasing age. Five-year net survival in men ranges from 83% in 15-49 year olds to 67% in 70-89 year-olds for patients diagnosed with penile cancer in England during 2009-2013.[1]

Penile Cancer (C60), Five-Year Net Survival by Age, England, 2009-2013

References

  1. Muller P, Belot A, Morris M, Rachet B, Cancer Research UK Cancer Survival Group, London School of Hygiene and Tropical Medicine. Net survival and the probability of cancer death from rare cancers. Available from http://csg.lshtm.ac.uk/rare-cancers/. Accessed July 2016.

About this data

Data is for: England, 2009-2013, ICD-10 C60

Last reviewed:

Five-year relative survival for penile cancer in men in England (70%) is similar to the average for Europe (68%). Wales (74%), Scotland (68%) and Northern Ireland (68%) are also similar to the European average.[1] Across the European countries for which data is available, five-year relative survival in men ranges from 50% (Slovakia) to 83% (Norway).[1]

Penile Cancer (C60, C63), Age-Standardised Five-Year Relative Survival, Males (Aged 15+), European Countries, 2000-2007

Data consists of both observed and predicted 5-year relative survival. Where sufficient follow-up was not available for recently diagnosed patients the period approach was used to predict 5-year cohort survival.

Possible explanations for persistent international differences in survival include differences in cancer biology, use of diagnostic tests and screening, stage at diagnosis, access to high-quality care, and data collection practices.[1]

References

  1. De Angelis R, Sant M, Coleman MP, et al. Cancer survival in Europe 1999-2007 by country and age: results of EUROCARE-5 - a population-based study. Lancet Oncol 2014;15:23-34 

About this data

Data is for: 29 European countries, patients diagnosed in 2000-2007 and followed up to 2008, penile cancer (International Classification of Diseases for Oncology [ICD-O-3] C60, C63).

Last reviewed:

Cancer stats explained

See information and explanations on terminology used for statistics and reporting of cancer, and the methods used to calculate some of our statistics.

Citation

You are welcome to reuse this Cancer Research UK content for your own work.
Credit us as authors by referencing Cancer Research UK as the primary source. Suggested styles are:

Web content: Cancer Research UK, full URL of the page, Accessed [month] [year].
Publications: Cancer Research UK ([year of publication]), Name of publication, Cancer Research UK.
Graphics (when reused unaltered): Credit: Cancer Research UK.
Graphics (when recreated with differences): Based on a graphic created by Cancer Research UK.

When Cancer Research UK material is used for commercial reasons, we encourage a donation to our life-saving research.
Send a cheque payable to Cancer Research UK to: Cancer Research UK, Angel Building, 407 St John Street, London, EC1V 4AD or

Donate online

Acknowledgements

We are grateful to the many organisations across the UK which collect, analyse, and share the data which we use, and to the patients and public who consent for their data to be used. Find out more about the sources which are essential for our statistics.

Rate this page:

Currently rated: 1.8 out of 5 based on 5 votes
Thank you!
We've recently made some changes to the site, tell us what you think

Share this page